Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Alliance Pharma unveils big board reshuffle with deputy CEO to become CEO, and a new chairman

The AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018
It added that Dawson, who founded Alliance in 1996, will remain on the board as a non-executive director

Alliance Pharma PLC (LON:APH) has unveiled the succession of its deputy CEO to CEO, the current CEO's transition to a non-executive role, and the appointment of a new chairman.

In a statement, the AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018.

READ: Alliance Pharma brings on board its third international product with US$17.5mln Vamousse deal

It added that Dawson, who founded Alliance in 1996, will remain on the board as a non-executive director.

Alliance Pharma also announced that following a search process involving internal and external candidates, as of today, David Cook - a non-executive director of the company for almost four years - will take over as its non-executive chairman from Andrew Smith, who will step down from Alliance's board. 

Cook is a chartered accountant who worked in a professional practice for 13 years with PwC, following which he has worked for 14 years in the pharmaceutical industry, including having roles at EUSA Pharma Inc, Jazz Pharmaceuticals Ltd and Biotie Therapies Corporation. He is currently chief financial officer of Ellipses Pharma Limited.

Close collaborations

Commenting on the Board changes, John Dawson said: "Peter Butterfield and I have worked closely together since he joined Alliance following our acquisition of Cambridge Laboratories eight years ago.

“His career path has been impressive and his capabilities give the Board the utmost confidence that, as CEO, Peter will be highly effective in driving the Company forward.”

The outgoing CEO added: "David Cook has been an invaluable Board member over the past four years and we are delighted that he has agreed to chair the Board as the Company continues on its growth trajectory.”

Butterfield, Alliance's Deputy CEO, commented: "I am delighted to be taking on the leadership of Alliance as it continues to grow. It has been a real pleasure working alongside John and I'm very pleased that he has decided to continue his involvement with the Company as a non-executive director."

In late afternoon trading, Alliance Pharma shares were off 0.7% at 67.2p.

 -- Adds share price --

View full APH profile View Profile

Alliance Pharma plc Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use